Peter Attia· MD
The patients who did bipolar antigen therapy and then did enzalutamide had significantly greater survival 37 months versus 28 months than enzalutamide which is the standard of care
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
The patients who did bipolar antigen therapy and then did enzalutamide had significantly greater survival 37 months versus 28 months than enzalutamide which is the standard of care
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the patients who did bipolar antigen therapy and then did enzolutamide had significantly greater survival 37 months versus 28 months then enzolutamide which is the standard of care the cost of enzolutomide is 8 000 a month the cost of 400 milligrams of testosterone is about 100 a month
the Transformer trial this is mind-blowing so they took about 200 patients who had castrate resistant metastatic prostate cancer and they said okay and if they became resistant to abiodarone the treatment of care is enzolutomide which is an androgen receptor blocker this is instead of giving everyone enzolutamide we're going to give half the men high doses of testosterone okay so let's see what happens so they gave them enzoluted or high Dosa testosterone they found that the overall survival between the two groups was the same no different but the difference in quality of life was significantly better on the patients